Higano CS - Search Results

1

Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.

Higano CS, Goodman P, Craig JB, Kish JA, Rivkin SE, Wolf M, Crawford ED. Higano CS, et al. Invest New Drugs. 1991 Nov;9(4):361-3. doi: 10.1007/BF00183582. Invest New Drugs. 1991. PMID: 1804814 Clinical Trial.

2

Combined treatment with chemotherapy and neutron irradiation for limited non-small-cell lung cancer: a Southwest Oncology Group Study.

Livingston RB, Griffin BR, Higano CS, Laramore GE, Rivkin SE, Goldberg RS, Schulman SF. Livingston RB, et al. Among authors: higano cs. J Clin Oncol. 1987 Nov;5(11):1716-24. doi: 10.1200/JCO.1987.5.11.1716. J Clin Oncol. 1987. PMID: 2824705 Clinical Trial.

3

A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study.

Higano CS, Crowley JJ, Veith RV, Livingston RB. Higano CS, et al. Invest New Drugs. 1997;15(2):153-6. doi: 10.1023/a:1005869008452. Invest New Drugs. 1997. PMID: 9220295 Clinical Trial.

4

A weekly cisplatin-based induction regimen for extensive non-small cell lung cancer. A Southwest Oncology Group study.

Higano CS, Crowley J, Livingston RB, Goodwin JW, Barlogie B, Stuckey WJ. Higano CS, et al. Cancer. 1991 May 15;67(10):2439-42. doi: 10.1002/1097-0142(19910515)67:10<2439::aid-cncr2820671007>3.0.co;2-6. Cancer. 1991. PMID: 1849785 Clinical Trial.

5

Cyclophosphamide, vincristine, cisplatin, VP-16 and radiation therapy in extensive small-cell lung cancer. A Southwest Oncology Group Study.

Collins C, Higano CS, Livingston RB, Griffin BR, Keppen MD, Miller TP. Collins C, et al. Among authors: higano cs. Cancer Chemother Pharmacol. 1989;24(2):128-32. doi: 10.1007/BF00263134. Cancer Chemother Pharmacol. 1989. PMID: 2543513

6

Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder.

Russell KJ, Boileau MA, Higano C, Collins C, Russell AH, Koh W, Cole SB, Chapman WH, Griffin TW. Russell KJ, et al. Int J Radiat Oncol Biol Phys. 1990 Sep;19(3):693-9. doi: 10.1016/0360-3016(90)90498-9. Int J Radiat Oncol Biol Phys. 1990. PMID: 2211217

7

Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.

Higano CS, Berlin J, Gordon M, LoRusso P, Tang S, Dontabhaktuni A, Schwartz JD, Cosaert J, Mehnert JM. Higano CS, et al. Invest New Drugs. 2015 Apr;33(2):450-62. doi: 10.1007/s10637-015-0217-7. Epub 2015 Mar 7. Invest New Drugs. 2015. PMID: 25749986

8

Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study.

Russell KJ, Boileau MA, Ireton RC, Higano CS, Collins C, Koh WJ, Griffin BR, Chapman WH, Griffin TW. Russell KJ, et al. Among authors: higano cs. Radiology. 1988 Jun;167(3):845-8. doi: 10.1148/radiology.167.3.3363151. Radiology. 1988. PMID: 3363151

9

Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial.

Higano CS, Livingston RB. Higano CS, et al. Cancer Chemother Pharmacol. 1989;23(4):259-62. doi: 10.1007/BF00451653. Cancer Chemother Pharmacol. 1989. PMID: 2647313 Clinical Trial.

10

Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer.

Mortimer JE, Higano C. Mortimer JE, et al. Cancer Invest. 1988;6(2):129-32. doi: 10.3109/07357908809077039. Cancer Invest. 1988. PMID: 3259900

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters